Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AFLAC Incorporated (AFL) vs TransMedics Group Inc (TMDX) Price & Performance

AFLAC IncorporatedTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

AFLAC Incorporated vs TransMedics Group Inc — how do they compare? AFLAC Incorporated trades at $120.88 (market cap $60.70B), while TransMedics Group Inc trades at $87.18 (market cap $3.10B). The key difference: AFLAC Incorporated is far larger — about 19.6× TransMedics Group Inc's market cap, and AFLAC Incorporated pays a 2.02% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.

AFLTMDX
Market Cap
$60.70B$3.10B
Sector
FinancialsTechnology
52-Week High
$129.55$150.42
52-Week Low
$103.55$61.99
Enterprise Value
$70.65B$3.49B
Dividend Yield
2.02%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AFLAC Incorporated

AFL trades at $121.09, down 0.7% on the day, with a bullish overall technical signal but bearish moving averages and oscillators. The stock shows strong profitability with a 26.59% net income margin and 16.91% ROE, though recent quarters have seen EPS misses. Revenue declined to $17.36B in 2025, with net income of $3.65B. Recent news highlights AFL's rebranding of network services and ongoing dividend commitments.

Outlook is mixed; solid fundamentals and a 43-year dividend growth history support income investors, but near-term headwinds include revenue pressure in Japan and FX impacts. Analyst consensus is cautious with a $118 price target below current levels, suggesting limited upside amid execution risks and competitive pressures.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AFLAC Incorporated

Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.

Read more on AFL

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX